Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: insulin degludec Clear all

Conditions: Diabetes Mellitus
Interventions: Degludec, Standard long-acting; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec/insulin aspart, insulin aspart, insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, placebo, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 67
States / cities: Anaheim, California • Concord, California • Escondido, California + 59 more

Conditions: Type 2 Diabetes
Interventions: INS068 injection, Insulin Degludec; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Huntington Park, California • Lincoln, California • Lomita, California + 10 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 26 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 66
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 60 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin glargine, insulin degludec, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 18
States / cities: Inglewood, California • Los Angeles, California • Redlands, California + 14 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Concord, California • Los Angeles, California • Montclair, California + 20 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 94
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more

Conditions: Type 2 Diabetes
Interventions: Degludec, Glargine, Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 27
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 24 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 32
States / cities: Fresno, California • La Mesa, California • Lancaster, California + 26 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 86
States / cities: Bay Minette, Alabama • Birmingham, Alabama • Huntsville, Alabama + 80 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Mesa, Arizona • Fresno, California • Greenbrae, California + 39 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 7,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 267
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more

Conditions: Diabetes, Healthy
Interventions: insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 62
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 57 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GLP-1 receptor agonist, Insulin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: LY900014, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Encino, California • Fresno, California • Huntington Beach, California + 34 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 45
States / cities: Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more

Search by objective public record fields.

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Comparison of Two NN1250 Formulations in Healthy Volunteers

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus